Digital Tools for Assessment of Motor Functions and Falls in ALS
Study Details
Study Description
Brief Summary
This is a 48-week single arm study that incorporates digital tools for assessing motor function as part of an ALS telemonitoring program. During the study, neck- and wrist-worn "activity sensors" (PAMSys, BioSensics, Newton, MA) that will be worn by subjects while performing tasks of daily living. Subjects will also complete a motor, speech, and handwriting assessment during site visits. Subjects will complete a digital home assessments of speech, handwriting, and pattern tracing tasks throughout the study, and report any falls which occur on the study tablet. The investigators will explore whether functional changes are sensitive to self-reported changes on the ALS Functional Rating Scale - Revised (ALFRS-R) over the length of the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Many of the recognized intrinsic factors for falls are commonly seen in ALS, including advanced age, muscle weakness, gait and balance problems, and previous falls. The American Academy of Neurology ALS Quality Standards Committee recommends querying patients for falls occurring in the past 12 months, indicating that prevention of falls is an important part of disease management. Despite this, the determinants and prevention of falls in this population is critically understudied.
Among frail older adults, fallers (those who reported at least 1 fall in the last 6-months) spent more than twice as much time walking as non-fallers (those who reported no falls in the last 6-months). For these individuals, the best predictors of falling are measures related to activity exposure, such as time spent walking, average walking bout duration, or steps per day. Activity metrics of cadence variability, peak vertical acceleration variability, average duration of episodes of walking, frontal acceleration variability, average peak vertical acceleration, and average cadence have been shown to be associated with fall risk. During walking, individuals with ALS have increased and highly variable gait cycle time (time to complete a full walking cycle), along with reduced stride length with increased variability in stride length compared to healthy controls.
The ability to observe changes in gait and posture has rapidly advanced around a revolution in mobile health technology. Inertial measurement units (IMUs), a standard inclusion of nearly all new smartphone/smartwatch devices, are small electronic chips that detect different aspects of inertial change, notably linear acceleration, angular velocity, and position relative to the magnetic field of the earth. Unlike their expansive use in movement disorders like Parkinson's disease, IMU-based gait assessment has been largely absent in ALS, despite the rapid changes to gait that may occur. The standard model for assessing and acting upon functional motor changes, including those impacting gait and falls, occurs roughly once every three months when patients are seen in the outpatient setting. Furthermore, self-reporting of falls has been shown to suffer from recall bias, resulting in low sensitivity and underreporting of fall events. In summary, patients with a rapidly progressing neurodegenerative disease, who in the standard care setting receive physical assessment motor function every three months, might stand to benefit from a home-based, objective biomarker for functional motor changes.
Study Design
Outcome Measures
Primary Outcome Measures
- Change in Physical Activity at 10 months [baseline and visit 4 (an average of 10 months)]
Changes in physical activity from baseline to 10 months will be assessed. Physical activity will be quantified by measuring number of taken steps per day and will be measured using a validated wearable sensor named PAMSys. Monitoring of physical activity will be done during 72 hours at baseline and 72 hours at 10 months.
Secondary Outcome Measures
- Change from baseline in total lower limb muscle strength at end of study [baseline and end of study (an average of 1 year)]
Strength testing is performed by the attending neurologist at clinical appointments. Bilateral hip flexion, knee extension and flexion, and foot dorsiflexion strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 40. Change in total lower limb strength score over study period will be calculated.
- Change from baseline in total upper limb muscle strength at end of study [baseline and end of study (an average of 1 year)]
Strength testing is performed by the attending neurologist at clinical appointments. Bilateral deltoids, biceps, triceps, wrist extension, and interossei strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 50. Change in total upper limb strength score over study period will be calculated.
- Change from baseline in total upper limb reflexes at end of study [baseline and end of study (an average of 1 year)]
Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral biceps, triceps, and brachioradialis reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 24. Change in total upper limb reflexes over study period will be calculated.
- Change from baseline in total lower limb reflexes at end of study [baseline and end of study (an average of 1 year)]
Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral patellar and achilles reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 16. Change in total lower limb reflexes over study period will be calculated.
- Change from baseline in Forced Vital Capacity at end of study [baseline and end of study (an average of 1 year)]
Forced vital capacity (FVC) is collected at clinical appointments. FVC is expressed as a percentage (%) of predicted volume against an age, height, and ethnicity matched standard. Change in FVC over this time period will be calculated.
- Change from baseline in total ALSFRS-R at end of study [baseline and end of study (an average of 1 year)]
ALS Functional Rating Scale-Revised (ALSFRS-R) measures function in 12 domains. The total score ranges from 48 (normal function) to 0 (no function). Change in total score over this time period will be calculated.
- Change from baseline in ALSFRS-R gross motor subscore at end of study [baseline and end of study (an average of 1 year)]
ALS Functional Rating Scale-Revised (ALSFRS-R) gross motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated.
- Change from baseline in ALSFRS-R fine motor subscore at end of study [baseline and end of study (an average of 1 year)]
ALS Functional Rating Scale-Revised (ALSFRS-R) fine motor subscore measures function in 3 domains. The total subscore ranges from 12 (normal function) to 0 (no function). Change in total subscore over this time period will be calculated.
- Change from baseline in "Falls Efficacy Scale - International" total score at end of study [baseline and end of study (an average of 1 year)]
The Falls Efficacy Scale - International (FES-I) is collected at study visits. The total score ranges from 64 (high concern about falling) to 0 (no concern about falling). Change in total score over this time period will be calculated.
- Change from baseline in "Fatigue Severity Scale" total score at end of study [baseline and end of study (an average of 1 year)]
The Fatigue Severity Scale is collected at study visits. The total score ranges from 63 (high fatigue) to 9 (low fatigue). Change in total score over this time period will be calculated.
- Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" weakness subscale at end of study [baseline and end of study (an average of 1 year)]
The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The weakness subscale total score ranges from 21 (high fatigue) to 7 (low fatigue). Change in total score over this time period will be calculated.
- Change from baseline in "Neurological Fatigue Index - Motor Neuron Disease" energy subscale at end of study [baseline and end of study (an average of 1 year)]
The Neurological Fatigue Index - Motor Neuron Disease is collected at study visits. The energy subscale total score ranges from 18 (high fatigue) to 6 (low fatigue). Change in total score over this time period will be calculated.
- Change from baseline in speaking rate at end of study [baseline and end of study (an average of 1 year)]
Subjects will complete the audio recording of a standard reading passage every two weeks. The speaking rate will be calculated from this audio, and the change in speaking rate over the study period will be calculated.
- Change from baseline in 3-meter Timed-Up-and-Go at end of study [baseline and end of study (an average of 1 year)]
3-meter timed-up-and-go task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated.
- Change from baseline in 10 meter walk at end of study [baseline and end of study (an average of 1 year)]
A 10-meter walk task is recorded at study visits. The best time of three trials is recorded. Change in best time over the study period will be calculated.
- Handwriting Assessment: Change from baseline in handwriting speed at end of study [baseline and end of study (an average of 1 year)]
As part of the Handwriting Assessment Battery completed at study visits, subjects will copy a standard sentence from a prompt in the booklet. The change in writing speed for this copying task over the study period will be calculated.
- Handwriting Assessment: Change from baseline in legibility at end of study [baseline and end of study (an average of 1 year)]
As part of the Handwriting Assessment Battery (HAB) completed at study visits, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated.
- Digital Handwriting Assessment: Change from baseline in handwriting speed at end of study [baseline and end of study (an average of 1 year)]
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will copy a standard sentence from a prompt on the tablet. The change in writing speed for this copying task over the study period will be calculated.
- Digital Handwriting Assessment: Change from baseline in legibility at end of study [baseline and end of study (an average of 1 year)]
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will print the alphabet in upper and lowercase, as well as the numbers 1-12. Legibility will be determined as the percent of individual characters rated as legible according to the HAB handbook. The change in character legibility over the study period will be calculated.
- Digital Handwriting Assessment: Change from baseline in spiral tracing speed at end of study [baseline and end of study (an average of 1 year)]
As part of the Digital Handwriting Assessment performed every two weeks on the study tablet, subjects will be timed as they trace the outline of a spiral. The change in time to complete the tracing over the study period will be calculated.
- Fall Event Detections [end of study (an average of 1 year)]
Fall events (falls and near-falls) detected by the sensor are registered on the study tablet. The total number of fall events registered over the course of the study is a secondary outcome.
- Fall Event Reports [end of study (an average of 1 year)]
Subjects enter fall event reports in the study tablet. The total number of reports reported over the course of the study is a secondary outcome
- Adherence: Tablet Assessments [end of study (an average of 1 year)]
Total number of assessments (handwriting, speech, and pattern tracing) completed on the tablet over the study period.
- Adherence: Fall Sensor [end of study (an average of 1 year)]
Total number of hours registered with wearing the fall sensor over the study period.
- Adherence: Activity Sensor [end of study (an average of 1 year)]
Total number of hours registered with wearing the activity sensors over the study period.
Eligibility Criteria
Criteria
Inclusion Criteria
-
Diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria [Brooks2000], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).
-
18 years of age or older;
-
ALSFRS-R walking sub-score of either 4 (normal gait), 3 (early ambulation difficulties), or 2 (walking with assistance);
-
Fluent in written and spoken English.
Exclusion Criteria
-
Neurological or orthopedic problems independent of their inclusionary diagnosis that affects their gait;
-
Pregnant or nursing woman;
-
Prisoner or institutionalized individuals;
-
Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Milton S. Hershey Medical Center | Hershey | Pennsylvania | United States | 17033 |
Sponsors and Collaborators
- Milton S. Hershey Medical Center
- BioSensics
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY13892